The Effect of Azathioprine on Serum Levels of Interleukin 6 and Soluble Interleukin 2 Receptor

References

• Harris E D, Jr. Rheumatoid arthritis: Pathophysiology and implications for therapy. N Engl J Med 1990; 322: 1277–89
   PubMed Web of Science ®Google Scholar
• Arend W P, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 305–15
   PubMed Web of Science ®Google Scholar
• Firestein G S, Xu W-D, Townsend K, Brodie D, Alvaro-Garcia J, Glaserbrook A, et al. Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophag colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med 1988; 168: 1537–86
   Google Scholar
• Firestein G S, Alvaro-Gracia J, Maki R. Quantitive analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990; 144: 3347–53
   PubMed Web of Science ®Google Scholar
• Hirano T. Interleukin-6. The Cytokine Handbook, A Thompson. Academic Press Ltd., London 1991; 169–90
   Google Scholar
• Aarden L A, DeGroot E R, Schaap O L, Lansdorp P M. Production of hybridoma growth factor by human monocytes. Eur. J Immunol 1987; 17: 1411–6
   Google Scholar
• Sanz I, Alboukrek D. Treatment of rheumatoid arthritis. Rheumatoid Arthritis, M Fischbach. Churchill Livingstone Inc., New York 1991; 99–184
   Google Scholar
• Gassmann A E, Van Furth R. The effect of azathioprine (Imuran) on the kinetics of monocytes and macrophages during the normal steady state and an acute inflammatory reaction. Blood 1975; 46: 51–64
   PubMedGoogle Scholar
• Arnett F C, Edworthy S M, Bloch D A, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24
   PubMed Web of Science ®Google Scholar
• Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55–63
   PubMed Web of Science ®Google Scholar
• Madhok R, Crilly A, Watson J, Capell H A. Serum interleukin 6 levels in rheumatoid arthritis: correlation with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993; 52: 232–4
   PubMed Web of Science ®Google Scholar
• Crilly A, Madhok R, Watson J, Capell H A. Serum concentrations of soluble interleukin 2 receptor in patients with rheumatoid arthritis. Effect of second line drugs. Ann Rheum Dis 1993; 52: 58–60
   PubMedGoogle Scholar
• Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu K, et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSF-2). Proc Natl Acad Sci USA 1985; 85: 5490–4
   Google Scholar
• Gauldie J, Richards C, Harnish D, Landsdorp P, Baumann H. lnterferon-β2/BSF-2 shares identity with monocyte-derived hepatocyte stimulating factor (HSF) and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987; 84: 7251–5
   PubMed Web of Science ®Google Scholar
• Nawata Y, Eugui E M, Lee S W, Allison A C. IL-6 is the principal factor produced by synovia of patients with rheumatoid arthritis that induces B-lymphocytes to secrete immunoglobulins. Ann NY Acad Sci 1989; 557: 230–9
   PubMedGoogle Scholar
• Zhou D, Munster A, Winchurch R A. Pathological concentration of interleukin 6 inhibit T cell responses via induction of TGF B. FASEB J 1991; 5: 2582
   PubMed Web of Science ®Google Scholar
• Schindler R, Mancilla J, Endres S, Ghorbani R, Clark S C, Dinarello C A. Correlation and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells-IL-6 suprresses IL-1 and TNF. Blood 1990; 75: 40–7
   PubMed Web of Science ®Google Scholar
• Aderka D, Le J M, Vilcek J. IL-6 inhibits lipopolysaccharide induced tumor necrosis factor production in cultured human monocytes, U937 cells and in mice. J Immunol 1989; 143: 3517–23
   PubMed Web of Science ®Google Scholar
• Houssiau F A, Devogelaer J P, Van Damme J, Nagant de Deuxchaishes C, Van Snick J. Interleukin 6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784–7
   PubMed Web of Science ®Google Scholar
• Gurne P A, Zuraw B L, Vaughan J H, Carson D A, Lotz M. Synovium as a source of interleukin-6 in vitro. J Clin Invest 1989; 83: 585–92
   PubMedGoogle Scholar
• Dasgupta B, Corkill M, Kirk B, Gibson T, Panayi G. Serial estimation of interleukin-6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 1992; 19: 22–5
   PubMedGoogle Scholar
• Madhok R, Crilly A, Murphy E, Smith J, Watson J, Capell H A. Gold therapy lowers interleukin-6 levels in rheumatoid arthritis. J Rheumatol 1993; 20: 630–3
   PubMedGoogle Scholar
• Madhok R, Crilly A, Watson J, Capell H A, Sturrock R D. The effect of second line drugs on soluble interleukin 2 receptor and interleukin 6 levels in rheumatoid arthritis (abstract). Clin Rheumatol 1991; 10: E10
   PubMedGoogle Scholar
• Barrera P, Boerbooms A MT, Janssen E M, et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumour necrosis factor α, and interleukin 6 levels in rheumatoid arthritis. Arthritis Rheum 1993; 36: 1070–9
   PubMed Web of Science ®Google Scholar
• Holt I, Cooper R G, Hopkins S J. Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur J Clin Invest 1991; 21: 479–84
   PubMedGoogle Scholar
• Swaak A J, Van Rooyen A, Nieuwenhius E, Aarden L A. Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. Scand J Rheumatol 1988; 17: 469–74
   PubMed Web of Science ®Google Scholar
• Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J 1989; 8: 3773–9
   PubMed Web of Science ®Google Scholar
• Mackiewicz A, Ganapathi M K, Schultz Branenec A, Weinstein J, Kelley M, et al. Transforming growth factor β I regulates production of acute phase proteins. Proc. Natl. Acad. Sci. USA 1990; 87: 1491–5
   PubMedGoogle Scholar
• Mackiewicz A, Speroff T, Ganapath M K, Kushner I. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 1991; 146: 3032–7
   PubMed Web of Science ®Google Scholar
• Chatila T, Wong R, Young M, Miller R, Terhorst C, Geha R S. An immunodeficiency characterised by defective signal transduction in T lymphocytes. N Engl J Med 1989; 320: 696–702
   PubMedGoogle Scholar
• Rubin L A, Kurman C C, Fritz M E, Biddison W E, Boutin B, Yarchoan R, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135: 3172–7
   PubMed Web of Science ®Google Scholar
• Rubin L A, Nelson D L. The soluble interleukin 2 receptor: biology, function and clinical application. Ann Intern Med 1990; 113: 619–27
   PubMed Web of Science ®Google Scholar
• Symons J A, Wood N C, DiGiovine F S, Duff G W. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol 1988; 141: 2612–8
   PubMed Web of Science ®Google Scholar